Direct interaction of DNMT inhibitors to PrP suppresses pathogenic process of prion.
10.1016/j.apsb.2019.04.001
- Author:
Dae-Hwan KIM
1
;
Chunyan REN
2
;
Chongsuk RYOU
1
;
Jiaojie LI
3
Author Information
1. Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan 15588, Republic of Korea.
2. Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
3. Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
- Publication Type:Journal Article
- Keywords:
DNMT;
Epigenetic regulation;
PrPC;
Prion;
Therapeutic compounds
- From:
Acta Pharmaceutica Sinica B
2019;9(5):952-959
- CountryChina
- Language:English
-
Abstract:
The conversion of the normal cellular prion protein (PrP) to the misfolded pathogenic scrapie prion protein (PrP) is the biochemical hallmark of prion replication. So far, various chemical compounds that inhibit this conformational conversion have been identified. Here, we report the novel anti-prion activity of SGI-1027 and its meta/meta analogue (M/M), previously known only as potent inhibitors of DNA methyltransferases (DNMTs). These compounds effectively decreased the level of PrP in cultured cells with permanent prion infection, without affecting PrP at the transcriptional or translational levels. Furthermore, SGI-1027 prevented effective prion infection of the cells. In a PrP aggregation assay, both SGI-1027 and M/M blocked the formation of misfolded PrP aggregates, implying that binding of these compounds hinders the PrP conversion process. A series of binding and docking analyses demonstrated that both SGI-1027 and M/M directly interacted with the C-terminal globular domain of PrP, but only SGI-1027 bound to a specific region of PrP with high affinity, which correlates with its potent anti-prion efficacy. Therefore, we report SGI-1027 and related compounds as a novel class of potential anti-prion agents that preferentially function through direct interaction with PrP.
